Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline predictors of androgen deprivation therapy response in advanced prostate cancer.

Mayo Clinic proceedings - 1 Mar 2012

Kohli Manish, Riska Shaun M, Mahoney Douglas W, Chai High S, Hillman David W, Rider David N, Costello Brian A, Qin Rui, Lamba Jatinder, Sahasrabudhe Deepak M, Cerhan James R

Abstract excerpt

OBJECTIVE: To evaluate whether germline variations in genes involved in sex steroid biosynthesis and metabolic pathways predict time to treatment failure for patients with advanced prostate cancer undergoing androgen deprivation therapy (ADT), because there are few known clinical predictors of response. PATIENTS AND METHODS: In a cohort of 304 patients with advanced prostate cancer undergoing ADT, we genotyped...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Genetic Association Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Markers

Share to Predictive Value of Tests

Share to Prostatic Neoplasms

Share to Spermatozoa

Share to Treatment Failure

Share to tRNA Methyltransferases

Source

Open in PubMed Open full text

Identifiers

PMID: 22386179
DOI: 10.1016/j.mayocp.2011.09.009
PMCID: PMC3538410

Genes

TRMT11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline predictors of androgen deprivation therapy response in advanced prostate cancer.PMID 22386179Read ↗

Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer.Semantic proximity Read ↗

Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate CancerSemantic proximity Read ↗

Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.Semantic proximity Read ↗

Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy.Semantic proximity Read ↗

SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.Semantic proximity Read ↗

Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.Semantic proximity Read ↗

Inherited variation in hormone-regulating genes and prostate cancer survival.Semantic proximity Read ↗

Vitamin D pathway gene variants and prostate cancer prognosis.Semantic proximity Read ↗

SRD5A polymorphisms and biochemical failure after radical prostatectomy.Semantic proximity Read ↗

Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy.Semantic proximity Read ↗

Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.